← Back to Search

Quality of Life Intervention for Early-Stage Lung Cancer

N/A
Recruiting
Led By Anurag K Singh
Research Sponsored by Roswell Park Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >= 18 years of age
Diagnosed with biopsy-proven stage I-II non-small cell lung cancer (NSCLC)
Must not have
Eligible for palliative-intent treatments or supportive care only
Diagnosed with stage III-IV NSCLC
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial studies how providing quality of life information affects decision-making in early-stage lung cancer patients choosing between surgery and radiation therapy. The goal is to help patients make better-informed decisions and feel more satisfied with their care.

Who is the study for?
This trial is for adults over 18 with early-stage lung cancer (stage I-II NSCLC) who can consent in English and are eligible for both surgery and SBRT. It's not suitable for those only eligible for one treatment, at later stages of cancer, pregnant women, or individuals unable to follow the study plan.
What is being tested?
The trial examines a quality of life intervention aimed at helping patients choose between surgery and SBRT. The goal is to reduce regret over their decision and improve satisfaction by providing them with quality of life outcome data during the decision-making process.
What are the potential side effects?
Since this trial involves best practices, informational interventions, and questionnaires rather than medical treatments or drugs, there are no direct physical side effects associated with participating in this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have been diagnosed with early-stage non-small cell lung cancer.
Select...
I am a candidate for both surgery and SBRT.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am only eligible for treatments aimed at easing symptoms.
Select...
My lung cancer is at an advanced stage (III or IV).
Select...
I am eligible for either surgery or SBRT, but not both.
Select...
I have difficulty making decisions due to cognitive impairment.
Select...
I am under the age of 18.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Decision regret
Secondary study objectives
Difference in consideration of regret
Quality of Life (EORTC QLQ-C30)
Quality of Life (QOL)

Side effects data

From 2020 Phase 3 trial • 177 Patients • NCT01817075
13%
Rash maculo-papular
10%
Skin and subcutaneous tissue disorders - Other, specify
1%
Mucositis oral
1%
Sepsis
1%
Skin ulceration
1%
Urticaria
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm I (CHG Cleansing Wipe)
Arm II (Control)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group A (QOL fact sheet)Experimental Treatment2 Interventions
Patients receive study QOL intervention fact sheet during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT. Patients have an opportunity to review the QOL fact sheet in person and discuss any questions with the treating physician(s).
Group II: Group B (usual care)Active Control2 Interventions
Patients receive usual care during the initial consult that occurs 4 weeks prior to the standard of care surgery or SBRT.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Non-Small Cell Lung Cancer (NSCLC) include chemotherapy, targeted therapy, and immunotherapy. Chemotherapy kills rapidly dividing cells, including cancer cells, but can also affect normal cells, leading to side effects. Targeted therapy uses drugs that specifically target genetic mutations or proteins involved in cancer cell growth, offering a more precise approach with potentially fewer side effects. Immunotherapy enhances the body's immune system to recognize and destroy cancer cells. Understanding these mechanisms helps NSCLC patients and their doctors make informed decisions about treatment options, balancing effectiveness with quality of life.
Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.

Find a Location

Who is running the clinical trial?

Roswell Park Cancer InstituteLead Sponsor
414 Previous Clinical Trials
33,572 Total Patients Enrolled
National Comprehensive Cancer NetworkNETWORK
120 Previous Clinical Trials
7,250 Total Patients Enrolled
Anurag K SinghPrincipal InvestigatorRoswell Park Cancer Institute
6 Previous Clinical Trials
1,776 Total Patients Enrolled

Media Library

Questionnaire Administration Clinical Trial Eligibility Overview. Trial Name: NCT05292521 — N/A
Non-Small Cell Lung Cancer Research Study Groups: Group A (QOL fact sheet), Group B (usual care)
Non-Small Cell Lung Cancer Clinical Trial 2023: Questionnaire Administration Highlights & Side Effects. Trial Name: NCT05292521 — N/A
Questionnaire Administration 2023 Treatment Timeline for Medical Study. Trial Name: NCT05292521 — N/A
~0 spots leftby Jan 2025